C
1.40
-0.03 (-2.10%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Citius Oncology, Inc. | - | - |
Stockmoo Score
0.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 95.88% |
| % Held by Institutions | 5.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Terrapin Asset Management, Llc | 30 Sep 2023 | 90,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2024 | Announcement | Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference |
| 12 Aug 2024 | Announcement | Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. |
| 09 Aug 2024 | Announcement | TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update |
| 05 Aug 2024 | Announcement | Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. |
| 05 Aug 2024 | Announcement | TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |